Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Figure 1 Flow diagram showing the patients with infiltrative hepatocellular carcinoma enrolled in the study. HBV: Hepatitis B virus.

Figure 2 Graph showing the effect of different levels of hepatitis B virus-DNA on long-term survival of patients and further subgroup analysis according to antiviral treatment. A: Kaplan Meier plot of progression-free survival in the hepatitis B virus (HBV)-DNA ≤ 2000 and HBV-DNA > 2000 groups; B: Kaplan Meier plot of overall survival (OS) in the HBV-DNA ≤ 2000 and HBV-DNA > 2000 groups; C: Kaplan Meier plot of Analysis of progression-free survival subgroup by antiviral therapy; D: Kaplan Meier plot of Analysis of OS subgroup by antiviral therapy. HBV: Hepatitis B virus.

Figure 3 Graph showing the prognostic model for predicting 9- and 12-months overall survival. OS: Overall survival; PVTT: Portal vein tumour thrombus; BCLC: Barcelona Clinic Liver Cancer.

Figure 4 Graph showing the operating characteristic evaluation plot for prognostic model. A: Graph showing the training set receiver operating characteristic (ROC) evaluation plot for 9-month prognostic prediction model; B: Graph showing the validation set ROC evaluation plot for 9-month prognostic prediction model; C: Graph showing the training set ROC evaluation plot for 12-month prognostic prediction model; D: Graph showing the validation set ROC evaluation plot for 12-month prognostic prediction model. AUC: Aure under the curve.

Figure 5 Graph showing the Calibration plots for prognostic model. A: Calibration plots for training set 9-months overall survival (OS); B: Calibration plots for validation set 9-months OS; C: Calibration plots for training set 12-months OS; D: Calibration plots for validation set 12-months OS.